Q: What is the biggest retirement investment mistake people make?
A: Being too conservative with their portfolio. People think, "I've accumulated this much," and their inclination is to put it in stable investments ��cash or bonds, but they run the risk of eroding their purchasing power. Their essential expenses will increase in retirement ��taxes will go up on their property, health care will go up, the cost of food will go up ��so they need an equity portfolio that is growing so it maintains or increases their purchasing power in the future.
Top 10 Information Technology Companies To Buy Right Now: BioTime Inc (BTX)
BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.
HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.
The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.
Human Embryonic Stem Cell Lines for Research Use
Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.
The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.
Human Embryonic Progenitor Cells
Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.
Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.
hES Cells Carrying Genetic Diseases
The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).
ESpan Cell Growth Media
The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.
ESpy Cell Lines
The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.
HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices
HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX ) has received the dreaded one-star ranking.
- [By John Udovich]
Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:
10 Best Long Term Stocks To Invest In 2014: Chromadex Corp (CDXC)
Chromadex Corporation, incorporated on June 19, 2008, is a provider of research and quality-control products and services to the natural products industry. The Company�� products are used by customers worldwide in the dietary supplement, food and beverage, cosmetic and pharmaceutical industries. The Company together with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and ingredients. On December 3, 2012, ChromaDex Inc. acquired Spherix Consulting Inc. The Company�� principal subsidiaries include ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc (Spherix).
The Company provides its clients in the food, supplement and pharmaceutical industries with solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations, and design and assessment of pre-clinical and clinical safety testing. It specializes in regulatory submissions for food and dietary supplement ingredients. For its clients involved in drug development within the pharmaceutical industry, the Company provides similar services, as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and investigational new drug writing.
Products and Services
The Company offers bulk raw materials for inclusion in dietary supplements, food, beverage and cosmetic products. Through its catalog, it supplies a range of products necessary to conduct quality control of raw materials and consumer products. The Company through Chromadex Analytics, provides a range of contract services ranging from routine contract analysis for the production of dietary sup! plements, cosmetics, foods and other natural products to elaborate contract research for clients in these industries. The Company provides a range of consulting services in the areas of regulatory support, new ingredient or product development, risk management and litigation support. With an addition of Spherix, it provides regulatory approval and scientific advisory services.
The Company competes with Sigma-Aldrich, Phytolab, US Pharmacopoeia, Extrasynthese, Covance, Eurofins, and Silliker Canada Co.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look:
10 Best Long Term Stocks To Invest In 2014: Forestar Group Inc (FOR)
Forestar Group Inc. (Forestar) is a real estate and natural resources company. The Company owns directly or through ventures almost 147,000 acres of real estate located in nine states and 12 markets and about 595,000 net acres of mineral interests. As of December 31, 2011, the Company had approximately 131,000 acres of timber on its 147,000 real estate acres and about 17,000 acres of timber under lease. During the year ended December 31, 2011, the Company generated revenues of $136 million. It operates in three segments: Real estate, Mineral resources and Fiber resources. Its real estate segment generated 78% of its 2011 consolidated revenues. The Company sells wood fiber from portions of its land, primarily in Georgia, and lease land for recreational uses. It leases its mineral interests to third parties for the exploration and production of oil and natural gas, principally in Texas and Louisiana. On January 20, 2012, it sold its 25% interest in Palisades West LLC to Dimensional Fund Advisors L.P. In September 2012, the Company acquired CREDO Petroleum Corp.
Real estate
In the Company�� real estate segment, it conducts an array of project planning and management activities related to the acquisition, entitlement, development and sale of real estate, primarily residential and mixed-use communities. It owns and manages its projects either directly or through ventures. Its development projects are principally located in the markets of Texas. The Company has over 16,000 acres entitled, developed and under development, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. In 2011, it sold over 17,000 acres of undeveloped land through its retail land sales program. In addition, it sold 112 entitled acres from two residential projects. The majority of its projects are single-family residential and mixed-use communities. During 2011, the Company acquired 180 substantially completed residential lots in Houston, Texas; three multifamily develo! pment sites located in Austin, Denver, and Dallas.
The Company develops lots for single-family homes and develops multifamily properties on its commercial tracts or other developed sites it may purchase. In addition, the Company sells commercial tracts that are ready for construction of buildings for retail, office, industrial or other commercial uses. It sells residential lots primarily to national and regional homebuilders and, to a lesser extent, local homebuilders. The Company has 75 entitled, developed or under development projects in seven states and 11 markets, principally in the markets of Texas, encompassing over 16,000 remaining acres, consisted of land planned for over 27,000 residential lots and about 2,500 commercial acres. It also markets and sells undeveloped land through its retail sales program.
Commercial tracts are developed internally or sold to or ventured with commercial developers that specialize in the construction and operation of income producing properties, such as apartments, retail centers, or office buildings. The Company also sells land designated for commercial use to regional and local commercial developers. It has about 2,500 acres of entitled land designated for commercial use. Cibolo Canyons is a mixed-use project in the San Antonio market area.
Mineral Resources
The Company owns mineral interests beneath approximately 595,000 net acres located in the United States, principally in Texas, Louisiana, Georgia and Alabama. It is engaged in leasing certain portions of these mineral interests to third parties for the exploration and production of oil and natural gas. Of the Company�� 595,000 net acres of mineral interests, about 515,000 net acres are available for lease. It has about 80,000 net acres leased for oil and natural gas exploration activities, of which about 32,000 net acres are held by production from over 530 oil and natural gas wells that are operated by others. During 2011, the Company acquired unproved le! asehold p! roperties associated with 13,000 net mineral acres in Alabama and Georgia.
The Company has about 251,000 net mineral acres in East Texas and about 144,000 net mineral acres in Louisiana located within the East Texas and Gulf Coast Basins. It has mineral interests in and around production trends in the Wilcox, Frio, Cockfield, James Lime, Pettet, Travis Peak, Cotton Valley, Austin Chalk, Haynesville Shale and Bossier formations. The Company has about 1,000 net mineral acres in the Fort Worth Basin. It also has mineral interests in and around the Barnett Shale. The Company has about 40,000 net mineral acres in Alabama and about 157,000 net mineral acres in Georgia. The Company did not drill any wells in 2011.
Fiber Resources
The Company has about 131,000 acres of timber it owns directly or through ventures and about 17,000 acres of timber under lease. In 2011, it sold to Temple-Inland, over 323,000 tons of timber from its lands. During 2011, about 131,000 acres of its land, primarily in Georgia, were leased for recreational purposes. During 2011, the Company sold 57,000 acres of timberland in Georgia, Alabama, and Texas.
Advisors' Opinion:- [By Andy Batts]
The shares of Forestar Group (FOR) are trading at ~30% discount to the company's NAV. The company operates in three business segments: real estate, oil and gas, and other natural resources. Forestar has a rich portfolio of assets and businesses, including 133,000 acres of real estate; 752,000 acres of oil and gas properties; 1.5 million acres of water rights; and 275,000 acres of timberland.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Forestar Group (NYSE: FOR ) , whose recent revenue and earnings are plotted below.
10 Best Long Term Stocks To Invest In 2014: Ishares Silver Trust (SLV)
iShares Silver Trust (the Trust) owns silver transferred to the Trust in exchange for shares issued by the Trust (Shares). Each Share represents a fractional undivided beneficial interest in the net assets of the Trust. The assets of the Trust consist primarily of silver held by the Trust�� custodian on behalf of the Trust. The sponsor of the Trust is iShares Delaware Trust Sponsor LLC (the Sponsor). The trustee of the Trust is The Bank of New York Mellon (the Trustee) and the custodian of the Trust is JPMorgan Chase Bank N.A., London branch (the Custodian).
The activities of the Trust are limited to issuing Baskets of Shares in exchange for the silver deposited with the Custodian as consideration, selling silver as necessary to cover the Sponsor�� fee, Trust expenses not assumed by the Sponsor and other liabilities and delivering silver in exchange for Baskets of Shares surrendered for redemption. Each deposit of silver for the creation of Baskets of Shares and each surrender of Baskets of Shares for the purpose of withdrawing Trust property (including if the trust agreement terminates) must be accompanied by a payment to the Trustee of a fee.
Advisors' Opinion:- [By salamat_uri]
Next, it will be important to monitor the relative performance of oil's most commonly correlated assets: Gold, the S&P 500, and the US Dollar. It might be easy to assume that any positive moves in oil will carry over into the rest of the commodities space, as well. Higher oil prices have led to projections that alternative commodities ETFs like the SPDR Gold Trust ETF (GLD) andiShares Silver Trust ETF (SLV) will be able to gain traction and move to new highs for the year. But the fact that this has not been the case suggests that the broader global framework is still not conducive to significant bull moves in commodities as a whole. The SPDR S&P 500 Trust ETF (SPY) is still trading at its own record highs but activity in the PowerShares DB US Dollar Index Bullish ETF (UUP) has much better potential to move prices in oil.
10 Best Long Term Stocks To Invest In 2014: ValueClick Inc.(VCLK)
ValueClick, Inc. provides various products and services that enable marketers to advertise and sell their products through online marketing channels primarily in the United States and the United Kingdom. The company?s Affiliate Marketing segment provides technology platforms, advertising network, and customer services, which enable advertisers to create their own commissioned online sales force comprising third-party Website publishers. This segment offers its services under the Commission Junction brand. Its Media segment provides digital marketing services and tailored programs under ValueClick Media brand name that enable marketers to create and increase awareness for their products and brands; attract visitors; and generate leads and sales through the Internet and mobile applications. The company?s Owned & Operated Websites segment offers its services through various Websites comprising Pricerunner and Smarter.com Websites, which enable consumers to research and comp are products from online and/or offline merchants; Couponmountain.com Website that enables consumers to locate coupons and deals related to products and services; and Investopedia.com Website, which provides information on various financial and investment topics, including a proprietary dictionary of financial terms. This segment also operates vertical content Websites that offer consumers information and reference material in various topics in healthcare, finance, travel, home and garden, education, and business services. Its Technology segment operates as an application service provider and offers technology infrastructure tools and consultative services that enable marketers to implement and manage their online display advertising, search engine marketing, and email campaigns. The company serves direct marketers, advertisers, advertising agencies, and traffic distribution partners. ValueClick, Inc. was founded in 1998 and is headquartered in Westlake Village, California.< /p> Advisors' Opinion:
- [By Brian Pacampara]
What: Shares of digital marketing company ValueClick (NASDAQ: VCLK ) plummeted 17% today after its quarterly results and outlook disappointed Wall Street.
- [By Rich Smith]
ValueClick got toggled off
Google's�mini-rival in the market for online ads, ValueClick (NASDAQ: VCLK ) , beat earnings by a couple of cents in yesterday's earnings report. Unfortunately, this good news isn't translating into good grades on Wall Street, as a whole series of analysts cut their ratings on the stock to various flavors of "hold." Stephens and Cantor Fitzgerald, Craig-Hallum and Raymond James -- one and all, the analysts are downgrading ValueClick today -- but why?
10 Best Long Term Stocks To Invest In 2014: China GengSheng Minerals Inc. (CHGS)
China GengSheng Minerals, Inc., through its subsidiaries, operates in the materials technology industry. It develops, manufactures, and sells a range of mineral-based, heat-resistant products. The company�s products include refractory products, industrial ceramics, fracture proppants, and fine precision abrasives. Its refractory products comprise castable, coating, and dry mix materials; low-cement and non-cement castables; and pre-cast roofs that are used as linings and key components in industrial furnaces, such as steel production furnaces, ladles, vessels, and other high-temperature processing machines that operate at high temperatures in various industries. The company�s industrial ceramic products consist of abrasive balls and tiles, valves, electronic ceramics, and structural ceramics that are used as components for various end products, such as fuses, vacuum interrupters, electrical components, mud slurry pumps, and high-pressure pumps in the electric power, elec tronic component, industrial pump, and metallurgy industries. Its fracture proppant products include ball-like pellets that are used to reach pockets of oil and natural gas deposits trapped in the fractures under the ground. The company�s fine precision abrasives are primarily used for the surface-polishing and slicing of precision instruments, such as solar panels, as well as in a range of areas, including machinery manufacturing, electronics, optical glass, architecture, industry development, semiconductor, silicon chip, plastic, and lens. China GengSheng Minerals, Inc. sells its products to customers in the iron, steel, oil, glass, cement, aluminum, chemical, and solar industries in China and other parts of Asia, North America, and Europe. The company was formerly known as China Minerals Technologies, Inc. and changed its name to China GengSheng Minerals, Inc. in July 2007. China GengSheng Minerals, Inc. is based in Gongyi, the People�s Republic of China.
Advisors' Opinion:- [By Bryan Murphy]
If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.
10 Best Long Term Stocks To Invest In 2014: Carrols Restaurant Group Inc.(TAST)
Carrols Restaurant Group, Inc., through its subsidiary, Carrols Corporation, owns and operates quick-casual and quick-service restaurants. It operates restaurants under the Burger King, Pollo Tropical, and Taco Cabana names. As of January 1, 2012, the company owned and operated 547 restaurants, including 298 Burger King, 91 Pollo Tropical and 158 Taco Cabana restaurants in 17 states in the United States. It also franchised 36 restaurants in Puerto Rico, Ecuador, Honduras, Trinidad, the Bahamas, and Venezuela, as well as in college campuses in Florida. The company was formerly known as Carrols Holdings Corporation and changed its name to Carrols Restaurant Group, Inc. in November 2006. Carrols Restaurant Group, Inc. was founded in 1960 and is headquartered in Syracuse, New York.
Advisors' Opinion:- [By James Brumley]
Larger restaurant chains can handle the lull. A less liquid small-cap name like Carrols Restaurant Group (TAST), however, feels the pain pretty intensely. That’s why shares are down about 8% this month.
- [By Bloomberg Businessweek]
Alamy McDonald's (MCD) may recently have struggled to lure customers, but it still does far more business at each location than rival burger chains. The average McDonald's restaurant in the U.S. drew $2.6 million in revenue last year. Average sales for No. 2 chain Burger King (BKW): $1.2 million, according to data from its largest franchisee, Carrols Restaurant Group (TAST). What accounts for this more-than-a-million gap? "Everything from marketing and site selection to product initiatives and franchisee selection have been historical factors," said Nick Setyan, vice president in charge of equity research at Wedbush Securities, in an email. Here are four factors that drive higher sales volumes at McDonald's: 1. McDonald's gets more customers during off-peak hours. Look no further than the strength of its breakfast business relative that of Burger King, says Darren Tristano, executive vice president at restaurant consultancy Technomic. Egg McMuffin is part of the fast-food vocabulary in a way Burger King can't match. And beverage and snack offerings such as McCafe and wraps have helped increase McDonald's sales between meals. The dramatic impact from off-peak business explains why chains such as Taco Bell (YUM) are entering the battle for morning customers, while others such as Starbucks (SBUX) are seeking more afternoon and evening business. 2. The power of the Happy Meal. McDonald's has the largest share of kids meal sales in the fast-food industry and gets about 10 percent of total sales from Happy Meals, the most commonly advertised child-oriented fast-food item on television. Burger King, meanwhile, is still trying to win back "parties with kids and seniors and women," said Josh Kobza, Burger King's chief financial officer, at a conference last year. One way to do that: "We got rid of the creepy king character that tended to scare away women and children." 3. McDonald's has an edge on efficiency. Despite recent operational challenges at McDonald's,
No comments:
Post a Comment